# Phase 3 overweight trials recruiting: 72 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 72 trials in phase 3 for overweight that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 overweight trials: 72 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 9 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/overweight

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 72
- Recruiting or not yet: 72
- Read on: November 19, 2026

## Trials

The 25 newest of 72, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07932925 | The Purpose of This Study is to Learn About the Safety and Effectiveness of Berobenatide in Women With Urine Leakage and With Obesity or... | Pfizer | Phase 3 | Not yet recruiting | Urinary Incontinence, Stress, Overweight and/or Obesity | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07932925) |
| November 6, 2026 | NCT07922330 | A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These... | AstraZeneca | Phase 3 | Not yet recruiting | Obesity, Overweight, Type 2 Diabetes Mellitus | 330 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07922330) |
| November 5, 2026 | NCT07919678 | A Study to Learn About Study Medicine Called Berobenatide in Adults With Knee Pain and Overweight or Obesity (VESPER-OA 1) | Pfizer | Phase 3 | Recruiting | Obesity, Overweight, Osteoarthritis of the Knee | 656 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07919678) |
| November 5, 2026 | NCT07918846 | A Clinical Study Testing Enicepatide in Participants Living With Overweight or Obesity and Cardiovascular Disease | Hoffmann-La Roche | Phase 3 | Not yet recruiting | Overweight, Obesity, Cardiovascular Disease | 8,200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07918846) |
| November 4, 2026 | NCT07915609 | A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Knee Osteoarthritis, Diabetes Melliuts, Type 2 | 756 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07915609) |
| October 28, 2026 | NCT07900633 | A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2 | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900633) |
| October 26, 2026 | NCT07896265 | Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes | Regeneron Pharmaceuticals | Phase 3 | Not yet recruiting | Overweight or Obesity Without Diabetes | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07896265) |
| October 19, 2026 | NCT07881458 | A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes | Eli Lilly and Company | Phase 3 | Recruiting | Obesity, Overweight, Diabetes Mellitus, Type 2 | 1,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07881458) |
| October 15, 2026 | NCT07874633 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight | 432 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874633) |
| October 13, 2026 | NCT07871409 | Home Self-administration of Maridebart Cafraglutide With Autoinjector in Adults Living With Obesity or Overweight | Amgen | Phase 3 | Recruiting | Obesity, Overweight | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07871409) |
| October 8, 2026 | NCT07866066 | Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Amgen | Phase 3 | Recruiting | Diabetes Mellitus, Type 2 | 1,300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07866066) |
| September 29, 2026 | NCT07845500 | A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity | 660 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07845500) |
| September 28, 2026 | NCT07844512 | Safety and Analgesic Efficacy of the Biased μ-Opioid Receptor Agonist Tegileridine for Post-Operative Analgesia in Patients Undergoing... | The First Hospital of Jilin University | Phase 3 | Recruiting | Pain Management, Overweight , Obesity, Respiration; Sleep Disorder | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07844512) |
| September 28, 2026 | NCT07843498 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight | 3,900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843498) |
| September 28, 2026 | NCT07843485 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Type 2 Diabetes | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843485) |
| September 28, 2026 | NCT07843472 | A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Established... | Hoffmann-La Roche | Phase 3 | Recruiting | Obesity or Overweight, Cardiovascular Disease | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07843472) |
| September 16, 2026 | NCT07823608 | A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight... | Pfizer | Phase 3 | Recruiting | Apnea, Sleep Disorders, Overweight and/or Obesity | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07823608) |
| September 16, 2026 | NCT07822061 | AMAZE 10: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People in Japan With Excess Body Weight Lose Weight | Novo Nordisk A/S | Phase 3 | Recruiting | Overweight, Obesity | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822061) |
| September 8, 2026 | NCT07806279 | Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk | Uppsala University | Phase 3 | Not yet recruiting | Cardiometabolic Syndrome, Obesity and Cardiovascular Risk, Overweight , Obesity | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806279) |
| August 31, 2026 | NCT07794774 | A Study to Learn About Safety and Effects of Once-monthly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JM) | Pfizer | Phase 3 | Recruiting | Obesity | 197 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794774) |
| August 31, 2026 | NCT07794761 | A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW) | Pfizer | Phase 3 | Recruiting | Obesity | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794761) |
| August 31, 2026 | NCT07794579 | A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1... | Eli Lilly and Company | Phase 3 | Recruiting | Overweight, Prediabetic State, Prehypertension, Obesity, Abdominal | 2,001 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07794579) |
| August 28, 2026 | NCT07792954 | A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or... | Pfizer | Phase 3 | Recruiting | Obesity, Overweight | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792954) |
| August 27, 2026 | NCT07790861 | A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems | Eli Lilly and Company | Phase 3 | Not yet recruiting | Obesity, Overweight | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07790861) |
| August 25, 2026 | NCT07784725 | A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2... | AstraZeneca | Phase 3 | Recruiting | Obesity or Overweight | 2,500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07784725) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 13 |
| [Novo Nordisk A/S](https://specstream.ai/data/clinical-trials/company/novo-nordisk-a-s) | 10 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 10 |
| [Hoffmann-La Roche](https://specstream.ai/data/clinical-trials/company/hoffmann-la-roche) | 7 |
| [Amgen](https://specstream.ai/data/clinical-trials/company/amgen) | 5 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 5 |
| Ascletis Pharma (China) Co., Limited | 2 |
| Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 2 |
| [Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/hangzhou-zhongmei-huadong-pharmaceutical-co-ltd) | 2 |
| [HK inno.N Corporation](https://specstream.ai/data/clinical-trials/company/hk-inno-n-corporation) | 1 |
| Kaiser Permanente | 1 |
| MindRank AI Ltd | 1 |
| Shahid Beheshti University of Medical Sciences | 1 |
| [Shanghai Minwei Biotechnology Co., Ltd](https://specstream.ai/data/clinical-trials/company/shanghai-minwei-biotechnology-co-ltd) | 1 |
| University of Virginia | 1 |
| University of Chicago | 1 |
| Carnot Laboratories | 1 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 1 |
| The First Hospital of Jilin University | 1 |
| Chendu DIAO Pharmaceutical Group CO., LTD. | 1 |
| [Innovent Biologics (Suzhou) Co. Ltd.](https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd) | 1 |
| Uppsala University | 1 |
| The University of Hong Kong | 1 |
| Hudson Biotech | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 45 |
| China | 30 |
| Japan | 23 |
| Poland | 19 |
| Spain | 18 |
| Canada | 18 |
| Germany | 18 |
| Puerto Rico | 15 |
| India | 15 |
| Taiwan | 15 |
| Australia | 14 |
| United Kingdom | 14 |
| South Korea | 14 |
| Mexico | 13 |
| Brazil | 13 |
| Czechia | 12 |
| Italy | 11 |
| Argentina | 10 |
| Belgium | 9 |
| Denmark | 8 |
| France | 8 |
| Turkey (Türkiye) | 8 |
| Hungary | 7 |
| Israel | 7 |
| Romania | 7 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Bottled water companies in the United States](https://specstream.ai/data/businesses/bottled-water-companies/united-states)
- [Mediators in the United States](https://specstream.ai/data/businesses/mediators/united-states)
- [Armenian restaurants in the United States](https://specstream.ai/data/businesses/armenian-restaurants/united-states)
- [Import and export companies in the United States](https://specstream.ai/data/businesses/import-and-export-companies/united-states)
- [Uzbek restaurants in the United States](https://specstream.ai/data/businesses/uzbek-restaurants/united-states)
- [Fmcg wholesalers in the United States](https://specstream.ai/data/businesses/fmcg-wholesalers/united-states)
